BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28350995)

  • 21. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality.
    McCowan C; Munro AJ; Donnan PT; Steele RJ
    Eur J Cancer; 2013 Mar; 49(5):1049-57. PubMed ID: 23182687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA; Newton J; Gray CS
    Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
    [No Abstract]   [Full Text] [Related]  

  • 23. Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
    Zanders MM; van Herk-Sukel MP; Vissers PA; Herings RM; Haak HR; van de Poll-Franse LV
    Br J Cancer; 2015 Jul; 113(3):403-10. PubMed ID: 26180924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
    Bauriedel G; Skowasch D; Schneider M; Andrié R; Jabs A; Lüderitz B
    Am Heart J; 2003 Feb; 145(2):343-8. PubMed ID: 12595854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
    Li J; Jian Z; Huang L; Guo H; Huang J; Qian D; Fu W; Li A; Song Y
    Biomed Pharmacother; 2009 Sep; 63(8):608-12. PubMed ID: 19019624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Jamieson DG; Parekh A; Ezekowitz MD
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H; Gondek K
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
    Alcocer F; Novak Z; Combs BR; Lowman B; Passman MA; Mujib M; Jordan WD
    J Vasc Surg; 2014 Apr; 59(4):950-5. PubMed ID: 24491238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
    Youn YN; Yi G; Lee S; Joo HC; Yoo KJ
    Am Heart J; 2014 Jun; 167(6):818-25. PubMed ID: 24890530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
    Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
    Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
    Rosa A; Canaple S
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1563-8. PubMed ID: 9092419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit of aspirin not surpassed by combining clopidogrel with aspirin in dual anti-platelet prevention of atherothrombotic events in high-risk patients : drug trends in cardiology.
    Cardiovasc J S Afr; 2006; 17(2):96, 98; discussion 98. PubMed ID: 16733607
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
    Lee BK; Lee SW; Park SW; Lee SW; Park DW; Kim YH; Lee CW; Hong MK; Kim JJ; Jang S; Chi HS; Park SJ
    Am J Cardiol; 2007 Aug; 100(4):610-4. PubMed ID: 17697815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
    Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.